SCHEMBL1309744

SCHEMBL1309744

CS(=O)(=O)N1CCN(Cc2nc3nc(-c4ccc5[nH]ccc5c4)nc(N4CCOCC4)c3s2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 10/20 0.55
PIK3CA P42336 16/20 0.55
PIK3CB P42338 10/20 0.55
PIK3CG P48736 9/20 0.55
MTOR P42345 4/20 0.53
ATR Q13535 2/20 0.53
CYP2C9 P11712 1/20 0.53
PIK3R1 P27986 5/20 0.48
PIK3C2A O00443 1/20 0.48
PLK4 O00444 1/20 0.48
PIK3R2 O00459 1/20 0.48
PIK3C2B O00750 1/20 0.48
GAK O14976 1/20 0.48
EPHB6 O15197 1/20 0.48
DAPK3 O43293 1/20 0.48
STK16 O75716 1/20 0.48
PIK3C2G O75747 1/20 0.48
NTRK1 P04629 1/20 0.48
NQO2 P16083 1/20 0.48
CSNK2A2 P19784 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1309310 0.90 PIK3CA (0.56) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1309232 0.89 PIK3CA (0.49) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1309524 0.83 PIK3CD (0.75) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1309034 0.83 PIK3CA (0.53) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1308900 0.83 PIK3CA (0.75) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1311871 0.81 PIK3CA (0.74) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1311868 0.80 PIK3CA (0.73) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1310382 0.78 PIK3CA (0.54) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1309916 0.78 PIK3CD (0.57) PIK3CDPIK3CAPIK3CBPIK3CGMTOR
SCHEMBL1309749 0.77 PIK3CA (0.75) PIK3CDPIK3CAPIK3CBPIK3CGMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-8921361-B2 Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes UNIVERSITY OF BASEL (CH) 2014-12-30 US disclosed
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2011-11-10 US disclosed
WO-2010052569-A2 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES UNIVERSITY OF BASEL (CH) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275762-A1 TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES MTOR, PIK3CA, PIK3CD PIK3CD 3/4885PIK3CA 2/4885PIK3CB 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.